Production of Chloroplast-Derived Monoclonal Antibodies

Introduction

Antibodies protect the body from toxic substances and invading pathogens. Antibody-based therapies are currently the largest segment of the global biopharmaceutical market. The therapeutic application of polyclonal antibodies is hindered by the lack of specificity and consistency between batches. Scientists later used hybridomas to create a method of monoclonal antibodies (mAbs) targeting an epitope. Currently, the use of monoclonal antibodies as a therapeutic drug is emerging at a rapid rate, but its production is too expensive to be suitable for most applications. While most biopharmaceuticals are traditionally produced in mammalian cell culture systems, plant-based recombinant expression systems have shown significant advantages. The application of appropriate post-translational modifications and the production of functionally active chloroplast-derived therapeutic proteins has paved the way for the production of cost-effective plant therapeutic proteins. The researchers established a chloroplast model using the codon-optimized Guys 13 gene and successfully produced a Guys 13 monoclonal antibody against the caries-causing surface antigen of Streptococcus mutans.

Fig. 1. PMF and production of recombinant anticancer monoclonal antibodies. (Mohammadinejad R, et al., 2019)

Solutions

Our engineers are passionate about engineering chloroplasts to produce therapeutic proteins for research to treat or prevent disease in humans or animals. Lifeasible is an expert in the field of recombinant protein research and development, with a variety of mature and comprehensive platforms and technologies, providing global customers with professional solutions for the production of chloroplast-derived monoclonal antibodies. The use of plants to produce anticancer monoclonal antibodies is very attractive. Our engineers are dedicated to developing platforms for the production of recombinant monoclonal antibodies (mAbs) using plant-based expression systems through improved and diversified transgenic technologies.

Here, we provide the expression of monoclonal antibodies and their derivatives from the chloroplasts of various plants, such as tobacco, alfalfa, Chinese cabbage, corn, and soybean. Since each plant species has its own physical and physiological characteristics that affect the expression and glycosylation of recombinant glycoproteins, we will help you carefully consider the choice of plant species to ensure successful antibody development. In addition, we combine glycoengineering in plants to provide a comprehensive solution for the production of recombinant anticancer mAbs with tailored N-glycan structures. The production solutions we provide for chloroplast-derived monoclonal antibodies mainly include:

· Expression of Recombinant mAb Proteins in Plants
We employed Agrobacterium and particle bombardment, an expression protocol for stable genetic transformation, to insert a gene of interest into the chloroplast genome to generate chloroplast transgenic plants that express and correctly fold antibodies with disulfide bonds. Furthermore, proper glycosylation is established in the chloroplast.

· Purification of Monoclonal Antibodies from Plants
We are working on developing several fusion protein strategies to increase recombinant protein production levels and efficient purification in plants. The most widely used are protein A or G based affinity chromatography to purify antibodies expressed in plants.

Features of Our Solutions

• Plants can reproduce indefinitely, providing inexpensive mAb protein production on a large scale under controlled conditions.
• Plants have the ability to assemble and modify multimeric mAb proteins.
• Monoclonal antibodies can fully recognize cancer cells.
• Two, three or four proteins can be co-expressed at high levels.
• This solution can be used to express a variety of antibodies and antigens with carbohydrate modifications.

The chloroplast-transformed monoclonal antibodies are safe and effective, and also have activity against foreign molecules, pathogens or tumor cells. Lifeasible has extensive knowledge and experience in the development and production processes of the chloroplast-derived monoclonal antibodies. Our mission is to provide customers with comprehensive, reliable, professional solutions to accelerate your research. If you are interested in our solutions for the production of chloroplast-derived monoclonal antibodies, please contact us at any time.

References

1. Moussavou G, Ko K, Lee J H, et al. Production of monoclonal antibodies in plants for cancer immunotherapy[J]. BioMed research international, 2015, 2015.
2. Mohammadinejad R, Shavandi A, Raie D S, et al. (2019) Plant molecular farming: production of metallic nanoparticles and therapeutic proteins using green factories[J]. Green chemistry. 21(8): 1845-1865.